The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Docetaxel and curcuminoids (CCM) combination in patients with castration-resistant prostate cancer (CRPC): A phase II study.
Hakim Mahammedi
No relevant relationships to disclose
Mélanie Pouget
No relevant relationships to disclose
Eloise Planchat
No relevant relationships to disclose
Herve Cure
No relevant relationships to disclose
Xavier Durando
No relevant relationships to disclose
Mathilde Bayet-Robert
No relevant relationships to disclose
Isabelle Van-Praagh
No relevant relationships to disclose
Marc Atger
No relevant relationships to disclose
Laurent Guy
No relevant relationships to disclose
Catherine Abrial
No relevant relationships to disclose
Philippe J. M. Chollet
No relevant relationships to disclose
Jean-Christophe Eymard
No relevant relationships to disclose